Migrainous Infarction: Rare Stroke Complication of Migraine with Aura

Definition

Migrainous infarction (MI) is an ischemic stroke occurring during a typical migraine with aura attack, with neuroimaging confirmation of infarct in a relevant territory, and not attributable to other causes. ICHD-3 criteria require:

  • Migraine with aura attack.
  • One or more aura symptoms persisting >60 minutes.
  • Neuroimaging shows ischemic infarct in corresponding territory.
  • Other causes excluded (cardioembolic, large vessel, small vessel, other determined/undetermined).

Epidemiology

  • Extremely rare: ~0.2–0.5% of all ischemic strokes; ~2–4 per 100,000 person-years.
  • Predominantly young women (mean age 30–40) with migraine with aura.
  • Posterior circulation (vertebrobasilar) slightly more common than anterior.

Pathophysiology (Hypothesized)

  • Cortical spreading depression (CSD): Prolonged depolarization → metabolic stress, oxidative injury, blood-brain barrier disruption.
  • Vasoconstriction: CSD-induced oligemia may progress to ischemia in vulnerable territories.
  • Hypercoagulability: Platelet activation, elevated vWF, reduced protein S during attacks.
  • Endothelial dysfunction: Impaired vasoreactivity, pro-thrombotic state.
  • Vascular anatomy: Hypoplastic vertebral/basilar artery, PFO (paradoxical embolism).

Clinical Presentation

  • Aura symptoms (visual, sensory, speech) that do not resolve within typical 60-minute window.
  • New focal deficits (hemiparesis, ataxia, dysarthria, visual field loss) coinciding with aura.
  • Headache may be less prominent than neurologic deficit.

Diagnosis

  • Emergent MRI brain (DWI/FLAIR) — gold standard for acute infarct.
  • MRA/CTA — vessel imaging.
  • Cardiac workup (echo, Holter, PFO assessment).
  • Hypercoagulable panel (especially if unprovoked).
  • Exclude mimics: MELAS, CADASIL, mitochondrial disorders, vasculitis.

Acute Management

  • IV thrombolysis (alteplase/tenecteplase): If within 4.5 hours of symptom onset and no contraindications. Benefit likely outweighs theoretical hemorrhage risk from CSD.
  • Mechanical thrombectomy: If large vessel occlusion (LVO) identified.
  • Avoid: Triptans, ergotamines, vasoconstrictors.
  • Antiplatelet/anticoagulation per stroke etiology (aspirin, DOAC if cardioembolic).
  • Admission to stroke unit; neurology + headache specialist co-management.

Secondary Prevention

  • High-efficacy migraine preventive (CGRP mAb, topiramate, beta-blocker) to reduce aura frequency.
  • Aggressive vascular risk factor control (BP, lipids, glucose, smoking).
  • Estrogen avoidance (if aura).
  • Antiplatelet therapy (aspirin 81 mg daily) often recommended long-term.
  • Consider PFO closure if recurrent cryptogenic stroke + PFO (per RESPECT/CLOSE criteria).

Prognosis

Generally favorable if small infarct; higher recurrence risk than general population. Long-term multidisciplinary follow-up essential.

Migraine - Related Articles